POPULAR VIDEOS

James Del Rosso, DO: Discussing Early Immune Activity Upon Ruxolitinib Cream Withdrawal

Dr. Del Rosso, JCAD’s Clinical Editor-in-Chief, reviews a poster presented by Volkova et al at the 2024 American Academy of Dermatology annual meeting. The poster presented findings from the TRuE-V long-term extension (LTE) study, which evaluated changes in serum biomarkers in patients with segmental vitiligo who were randomized in the LTE to apply the vehicle or continue using ruxolitinib 1.5% cream after both groups had used ruxolitinib cream in the parent studies.

Watch Now

Journal Review: Andrew Blauvelt

Andrew Blauvelt, MD, MBA, a dermatologist at the Oregon Medical Research Center in Portland, Oregon, discusses the impact Ruxolitinib cream has on itch in patients with atopic dermatitis which has been a predominant issue in disease symptoms.

Watch Now

Maui Derm NPPA Summer 2024 Conference Coverage

Hensin Tsao, MD, PhD: Melanoma Bootcamp

Expert Perspectives in Skin Barrier Care

JCADTV Coverage from the AAD Annual Meeting 2024

POPULAR SERIES

Dr. Strober focuses on difficult-to-treat areas in patients with psoriasis and the tremendous impact on quality of life this disease can have.

In this series, board-certified dermatologists discuss new and emerging treatments for patients with vitiligo.

In this four-video series, experts in the field of medical dermatology discuss current and new treatment options for psoriasis and vitiligo.

Andrew Blauvelt, MD, MBA, a dermatologist at the Oregon Medical Research Center in Portland, Oregon, discusses the impact Ruxolitinib cream has on itch in patients with atopic dermatitis which has been a predominant issue in disease symptoms.